These high diagnostic and prognostic accuracies, combined with strong analytical robustness7,11, make plasma p-tau highly attractive for clinical use and will have important roles to play in the era of anti-AD therapies, where clinicians will need to confirm the presence of the pathology before cognitively impaired patients can be prescribed Food and Drug Administration (FDA)-approved anti-amyloid drugs19. Here, MAPT is linked to Alzheimer disease.